UFP Industries to Report Fourth Quarter and Full Year 2024 Results on Monday, February 17, 2025
A live audio webcast of the call along with supporting materials will be available on the UFP Industries Investor Relations website at www.ufpinvestor.com/news-filings-reports#events---presentations. A webcast replay will be available on the company's website for at least 90 days following the call.
UFP Industries, Inc.
UFP Industries, Inc. is a holding company whose operating subsidiaries – UFP Packaging, UFP Construction and UFP Retail Solutions – manufacture, distribute and sell a wide variety of value-added products used in residential and commercial construction, packaging and other industrial applications worldwide. Founded in 1955, the company is headquartered in Grand Rapids, Mich., with affiliates in North America, Europe, Asia and Australia. UFP Industries is ranked #493 on the Fortune 500 and #128 on Industry Week's list of America's Largest Manufacturers. For more about UFP Industries, go to www.ufpi.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250205763881/en/
Contacts
Stanley ElliottDirector of Investor Relations616-364-6161 x7568
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
Smarsh Named to Inc. 5000 for 18th Consecutive Year
Prestigious annual ranking of the most successful private companies in America spotlights 3-year revenue growth of 114% at Smarsh PORTLAND, Ore., August 12, 2025--(BUSINESS WIRE)--Smarsh, the global leader in digital communications compliance and intelligence, today announced it has been named to the Inc. 5000 list of the fastest-growing private companies in America for the 18th year in a row. This remarkable achievement underscores nearly two decades of sustained growth, innovation, and customer impact in one of the most essential and rapidly evolving sectors of enterprise technology. Smarsh is one of only two organizations in the history of the Inc. 5000 to receive this recognition 18 times. Where Vision Meets Execution "Smarsh is honored to be recognized on the Inc. 5000 list for the eighteenth consecutive year," said Kim Crawford Goodman, Chief Executive Officer of Smarsh. "This achievement reflects how we've redefined sustainable growth and delivered lasting value for customers in financial services, government and beyond. It also speaks to our relentless pursuit of excellence across every sector we serve. By combining transformative technology with a forward-looking vision, we help our customers stay secure, competitive, and confident—especially as they navigate shifts like the rise of AI. This recognition is a testament to our people, our partners, and the culture of innovation and leadership that drives our continued success." Smarsh ranked No. 3437 on this year's list, reporting a three-year (2021–2024) revenue growth rate of 114%. The company's momentum is fueled by major innovations in compliance AI, including the industry's first solution for Microsoft Copilot Capture and an Intelligent Agent that applies cutting-edge AI to find risk in communications data efficiently. Smarsh supports a wide range of organizations, from emerging advisory firms to 18 of the top 20 global banks, helping them meet the requirements of the SEC, FINRA, and other regulators around the world. Execution That Delivers Results This recognition comes amid a year of strong momentum for Smarsh, marked by multiple accolades for its innovation, vision and culture. Recent honors include the 2025 Silver Globee Award for "Best Use of AI in Finance," a spot on the 2025 AIFINTECH100 list of the world's most innovative AI companies in financial services, and recognition as a 2025 USA TODAY Top Workplace. These accomplishments demonstrate leadership in delivering secure, scalable and future-ready solutions for the world's most regulated industries. "Making the Inc. 5000 is always a remarkable achievement, but earning a spot this year speaks volumes about a company's tenacity and clarity of vision," says Mike Hofman, editor-in-chief of Inc. "These businesses have thrived amid rising costs, shifting global dynamics, and constant change. They didn't just weather the storm—they grew through it, and their stories are a powerful reminder that the entrepreneurial spirit is the engine of the U.S. economy." For complete results of the Inc. 5000, visit About Smarsh Smarsh enables companies to transform oversight into foresight by surfacing business-critical signals in their digital communications. Serving the top banks, insurers, investment firms, and government agencies worldwide, Smarsh delivers cloud-native solutions that help organizations stay compliant, mitigate risk, and unlock the value of their communications data. Learn more at or follow us on LinkedIn. About Inc. Inc. is the leading media brand and playbook for the entrepreneurs and business leaders shaping our future. Through its journalism, Inc. aims to inform, educate, and elevate the profile of its community: the risk-takers, the innovators, and the ultra-driven go-getters who are creating the future of business. Inc. is published by Mansueto Ventures LLC, along with fellow leading business publication Fast Company. For more information, visit View source version on Contacts Media Contact press@ Sign in to access your portfolio
Yahoo
22 minutes ago
- Yahoo
Stifel Lowers Price Target for Commerce.com (CMRC), Keeps Buy Rating
Inc. (NASDAQ:CMRC) is one of the 14 Best Technology Penny Stocks to Buy According to Analysts. On July 31, Stifel reduced its price target for Inc. (NASDAQ:CMRC) from $9 to $8 while keeping a Buy rating. This decision came after the company reported Q2 2025 results and announced that it is rebranding its corporate name to Inc. (NASDAQ:CMRC). This brings together the company's three market-leading solutions, BigCommerce, Feedonomics, and Makeswift, to support the next era of agentic commerce. Inc. (NASDAQ:CMRC) has restructured its go-to-market strategy and positioned itself to benefit from the agentic commerce trend. The company's Q2 2025 results met Wall Street's expectations. Stifel described these results as 'a clean print across the board.' Despite lowering the price target, Stifel still believes Inc. (NASDAQ:CMRC) has a good risk/reward profile. The firm expects the company to experience a slight acceleration in revenue and margin improvements over the mid-term. Inc. (NASDAQ:CMRC) provides an open, AI-driven commerce ecosystem. The company offers solutions, tools, and systems that empower businesses to innovate, grow, and thrive. While we acknowledge the potential of CMRC as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 12 Best Performing AI Stocks So Far in 2025 and 14 Best Aggressive Growth Stocks to Buy According to Analysts. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
24 minutes ago
- Business Wire
Techcyte and Modella AI Announce a Research Collaboration with Modella AI's State-of-the-Art Agentic and Generative AI-Powered Diagnostic Pathology Platform
OREM, Utah--(BUSINESS WIRE)-- Techcyte, a leading provider of AI-powered digital diagnostics for anatomic and clinical pathology, today announced that its platform, Techcyte Fusion ™ (research use only (RUO) in the US, CE-IVDD-marked in Europe), now includes Modella AI, a biomedical artificial intelligence company at the forefront of computational pathology, as a partner in the Techcyte Fusion Partner Program. This collaboration brings together Modella AI's groundbreaking research-use only AI co-pilot for pathologists, PathChat ™, with Techcyte's integrated, cloud-based digital pathology platform—supporting the advancement of workflow efficiency and expanding access to advanced AI-powered pathology tools for research. 'Modella AI's commitment to innovation, including agentic AI, and Techcyte's unified pathology platform create a powerful research combination,' said Matt Smith, Chief Strategy Officer at Techcyte. Modella AI is a biomedical artificial intelligence company focused on improving pathology through generative and agentic AI. Its flagship research product, PathChat, enables intelligent interactions with digital slides—offering capabilities such as report summarization, image interpretation, and contextual question answering. An advanced research-use only version of the tool, PathChat DX, has been granted U.S. Food and Drug Administration Breakthrough Device Designation, reflecting the device's potential to provide a more effective diagnosis of a life-threatening or irreversibly debilitating condition. While this designation recognizes the potential of the technology, any use of PathChat within the Techcyte Fusion platform remains for research use only and is not intended for clinical diagnostic purposes. 'Modella AI's commitment to innovation, including agentic AI, and Techcyte's unified pathology platform create a powerful research combination,' said Matt Smith, Chief Strategy Officer at Techcyte. 'Together, our goal is delivering practical AI that pathologists can trust and that seamlessly integrates into their digital workflows.' 'We're excited to partner with Techcyte to bring our pathology-native AI to a broader research audience,' said Jill Stefanelli, President, Cofounder, and Chief Executive Officer at Modella AI. 'Integrating PathChat into the Fusion research platform supports the exploration of AI-assisted workflows in pathology and reflects our shared commitment to advancing digital innovation in the lab.' The integration of PathChat into Techcyte Fusion represents a significant step forward in operationalizing next-generation AI. As pathology workloads increase and case complexity grows, this collaboration represents an important step toward exploring AI capabilities in digital pathology research settings—all within the familiar Techcyte platform. For more information about the Techcyte Fusion Partner Program, visit About Techcyte Techcyte is aiming to transform the practice of pathology through a unified, AI-powered digital platform that streamlines complex workflows, integrates with core lab systems, and enhances communication across the lab. By partnering with leading laboratories, scanner manufacturers, diagnostic hardware providers, and AI developers, we deliver a unified digital pathology platform to labs and clinics around the world, furthering our mission to positively impact the health of humans, animals, and the environment. Visit for more information. Techcyte's anatomic and clinical pathology platform is for Research Use Only in the United States. About Modella Modella AI ( is a Boston-based biomedical AI company dedicated to advancing healthcare through the development of cutting-edge generative and agentic AI technologies. By combining expertise in artificial intelligence and pathology, Modella AI aims to deliver innovative solutions that empower clinicians, improve patient outcomes, and transform medical workflows. Disclaimer: PathChat ™, PathChat ™ DX and the Techcyte Fusion ™ platform are research-use only devices and are not commercially available in the United States (as they are not FDA cleared or approved). The Techcyte Fusion platform is commercially available in Europe for diagnostic use. The FDA Breakthrough Device Designation for PathChat DX does not imply FDA clearance or approval. This press release contains forward-looking statements based on current assumptions and forecasts. Modella AI and Techcyte assume no obligation to update these statements to reflect future events or developments.
